CS227019B2 - Method of preparing (-)-n-methyl-3-(2-methylphenyloxy)-3-phenylpropylamine - Google Patents

Method of preparing (-)-n-methyl-3-(2-methylphenyloxy)-3-phenylpropylamine Download PDF

Info

Publication number
CS227019B2
CS227019B2 CS818359A CS835981A CS227019B2 CS 227019 B2 CS227019 B2 CS 227019B2 CS 818359 A CS818359 A CS 818359A CS 835981 A CS835981 A CS 835981A CS 227019 B2 CS227019 B2 CS 227019B2
Authority
CS
Czechoslovakia
Prior art keywords
solution
salt
methyl
mixture
phenylpropylamine
Prior art date
Application number
CS818359A
Other languages
Czech (cs)
English (en)
Inventor
Bennie J Foster
Edward R Lavagnino
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CS227019B2 publication Critical patent/CS227019B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CS818359A 1980-11-14 1981-11-13 Method of preparing (-)-n-methyl-3-(2-methylphenyloxy)-3-phenylpropylamine CS227019B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20649880A 1980-11-14 1980-11-14

Publications (1)

Publication Number Publication Date
CS227019B2 true CS227019B2 (en) 1984-04-16

Family

ID=22766667

Family Applications (1)

Application Number Title Priority Date Filing Date
CS818359A CS227019B2 (en) 1980-11-14 1981-11-13 Method of preparing (-)-n-methyl-3-(2-methylphenyloxy)-3-phenylpropylamine

Country Status (28)

Country Link
EP (1) EP0052492B1 (xx)
JP (3) JPS57114555A (xx)
KR (1) KR830007508A (xx)
AT (1) ATE6422T1 (xx)
AU (1) AU540707B2 (xx)
CA (1) CA1181430A (xx)
CS (1) CS227019B2 (xx)
CY (1) CY1350A (xx)
DD (1) DD201139A5 (xx)
DE (1) DE3162445D1 (xx)
DK (1) DK161887C (xx)
EG (1) EG15458A (xx)
ES (1) ES507142A0 (xx)
FI (1) FI77018C (xx)
GB (1) GB2087883A (xx)
GR (1) GR75395B (xx)
HK (1) HK16087A (xx)
HU (1) HU185475B (xx)
IE (1) IE52170B1 (xx)
IL (1) IL64288A (xx)
MY (1) MY8700709A (xx)
NZ (1) NZ198953A (xx)
PH (1) PH17424A (xx)
PL (1) PL233786A1 (xx)
PT (1) PT73982B (xx)
RO (1) RO83309B (xx)
SU (1) SU1068034A3 (xx)
ZA (1) ZA817863B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
GB8823405D0 (en) * 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
AU642582B2 (en) * 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
EP0591434A4 (en) * 1991-06-26 1994-09-14 Sepracor Inc Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
ES2197144T3 (es) * 1991-11-15 2004-01-01 Sepracor Inc. Uso del isomero s(+) puro de fluoxetina para la preparacion de un medicamento contra la migraña.
EP1013275A3 (en) * 1991-11-26 2001-01-10 Sepracor, Inc. Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
EP0576766A1 (en) * 1992-06-29 1994-01-05 Novo Nordisk A/S Propanolamine derivatives, their preparation and use
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6548082B1 (en) 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
WO2000058262A1 (en) * 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
US6541668B1 (en) 1999-04-09 2003-04-01 Eli Lilly And Company Methods for preparing 3-arloxy-3-arylpropylamines and intermediates thereof
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
GB0229583D0 (en) 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
CA2560899A1 (en) * 2004-06-28 2006-01-12 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of atomoxetine hydrochloride
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US7473804B2 (en) 2004-07-22 2009-01-06 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006108120A1 (en) * 2005-04-05 2006-10-12 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
EP1889828A1 (en) * 2005-04-05 2008-02-20 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7485754B2 (en) 2005-07-08 2009-02-03 Apotex Pharmachem Inc. Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
CZ2005473A3 (cs) * 2005-07-21 2006-02-15 Zentiva, A. S Zpusob výroby hydrochloridu (R)-N-methyl-3-(2-methylfenoxy)-3-fenylpropylaminu (atomoxetinu)
EP1798215A1 (en) 2005-12-14 2007-06-20 SOLMAG S.p.A. Polymorph of atomoxetine hydrochloride in crystalline form
ITMI20061987A1 (it) * 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2008062473A1 (en) * 2006-10-31 2008-05-29 Cadila Healthcare Limited Process for preparing atomoxetine hydrochloride
CN100430370C (zh) * 2006-11-03 2008-11-05 华东理工大学 一种丙胺衍生物及其在制备托莫西汀中的应用
WO2009141833A2 (en) * 2008-04-17 2009-11-26 Ind-Swift Laboratories Limited An improved process for synthesizing highly pure atomoxetine
JP5309262B2 (ja) 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物
MX365663B (es) * 2013-11-08 2019-06-10 Lilly Co Eli Solucion de atomoxetina.
GR1008531B (el) 2014-03-21 2015-07-13 Λαμδα Φαρμακευτικα Εργαστηρια Εφαμροσμενης Ερευνας Και Αναπτυξης Α.Ε., Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη
EP3069715A1 (en) 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
CN106916074A (zh) * 2017-02-14 2017-07-04 万特制药(海南)有限公司 盐酸托莫西汀的制备
CN110294680A (zh) * 2018-03-22 2019-10-01 北京深蓝海生物医药科技有限公司 一种盐酸阿托莫西汀的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
JPS5283811A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Aryloxy phenyl propylamines and their salts
GB1596033A (en) * 1978-04-25 1981-08-19 Boots Co Ltd (-)-(2-methoxyphenyl) ethylamine
JPS5536403A (en) * 1978-07-28 1980-03-14 Nippon Iyakuhin Kogyo Kk Preparation of 1-benzazonine derivative
IT1113029B (it) * 1979-03-01 1986-01-20 Simes Processo per la separazione dei due isomeri ottici del moprololo e composizioni farmaceutiche dell'antipodo levogiro

Also Published As

Publication number Publication date
IE812661L (en) 1982-05-14
KR830007508A (ko) 1983-10-21
FI813589L (fi) 1982-05-15
FI77018C (fi) 1989-01-10
PH17424A (en) 1984-08-08
ATE6422T1 (de) 1984-03-15
EP0052492B1 (en) 1984-02-29
JPH037251A (ja) 1991-01-14
EP0052492A1 (en) 1982-05-26
JPH037250A (ja) 1991-01-14
GB2087883A (en) 1982-06-03
FI77018B (fi) 1988-09-30
JPS57114555A (en) 1982-07-16
RO83309A (ro) 1984-02-21
AU7742781A (en) 1982-05-20
IL64288A0 (en) 1982-02-28
JPH046698B2 (xx) 1992-02-06
NZ198953A (en) 1984-10-19
JPH0369885B2 (xx) 1991-11-05
DK502781A (da) 1982-05-15
GR75395B (xx) 1984-07-13
MY8700709A (en) 1987-12-31
SU1068034A3 (ru) 1984-01-15
HK16087A (en) 1987-02-27
JPH046699B2 (xx) 1992-02-06
ES8206440A1 (es) 1982-08-16
AU540707B2 (en) 1984-11-29
PL233786A1 (xx) 1982-05-24
DE3162445D1 (de) 1984-04-05
CA1181430A (en) 1985-01-22
CY1350A (en) 1987-04-24
PT73982A (en) 1981-12-01
DD201139A5 (de) 1983-07-06
EG15458A (en) 1986-09-30
HU185475B (en) 1985-02-28
DK161887C (da) 1992-03-16
RO83309B (ro) 1984-02-28
ZA817863B (en) 1983-06-29
PT73982B (en) 1983-11-23
ES507142A0 (es) 1982-08-16
DK161887B (da) 1991-08-26
IE52170B1 (en) 1987-07-22
IL64288A (en) 1985-04-30

Similar Documents

Publication Publication Date Title
CS227019B2 (en) Method of preparing (-)-n-methyl-3-(2-methylphenyloxy)-3-phenylpropylamine
US4626549A (en) Treatment of obesity with aryloxyphenylpropylamines
KR100412154B1 (ko) N-프로파길-1-아미노인단의r-에난시오머,염,및그들의조성물의사용
US5075338A (en) Method of treatment of learning deficiency
RU2057120C1 (ru) N-алкил-3-фенил-3-(2-замещенный фенокси)пропиламин или его фармацевтически приемлемая кислотно-аддитивная соль, способ его получения, фармацевтическая композиция, обладающая ингибирующей поглощение норминефрина активностью
WO1981003491A1 (en) Therapeutically useful tetralin derivatives
US5145870A (en) Aryloxyphenylpropylamines their preparation and use
EP0047536A2 (en) Substituted propylamines
US5220068A (en) Psychostimulant agent
NO128869B (xx)
FI101301B (fi) Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahyd roatsepiinijohdannaisten valmistamiseksi
US4465692A (en) Selective D-2 dopamine receptor agonist
HU205344B (en) Process for producing propaneamine derivatives
US4876282A (en) 1-Phenylalkylamines as selective serotonin uptake inhibitors
EP0537915B1 (en) N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
US4141993A (en) Compounds of diphenylcyclopentylamine type and methods for their preparation
US3175945A (en) Antihypertensive quaternary ammonium salts of 1:2:3:4-tetrahydroisoquinoline
KR820001304B1 (ko) 펜아탄올아민의 제조방법
NL7906216A (nl) Glaucine-zouten.
HU203474B (en) Process for producing pharmaceutical compositions for treating ulcus ventriculi
CS266314B2 (cs) Způsob výroby benzamidových derivátů
AU7179781A (en) Therapeutically useful tetralin derivatives
BE878563A (fr) Nouvelles alpha-alkyl-o-oxybenzylamines, leur preparation et leur application comme medicaments